|
Tue, 03/26/2019 - 10:09 |
Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System to Best-in-Class Medical Aesthetics Portfolio |
|
Thu, 03/21/2019 - 17:14 |
CoolSculpting and Sonja Morgan Talk Bikini Denial Just In Time For Summer |
|
Tue, 03/19/2019 - 21:26 |
CoolSculpting and Sonja Morgan Partner to Talk Bikini Denial |
|
Sun, 03/17/2019 - 19:33 |
Allergan Announces FDA Approval of AVYCAZ (ceftazidime and avibactam) for Pediatric Patients |
|
Wed, 03/13/2019 - 20:35 |
Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" -- Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting |
|
Sun, 03/10/2019 - 20:36 |
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine |
|
Wed, 03/06/2019 - 22:10 |
Allergan & Conde Nast International Announce International Content & Events Partnership for Beauty Decoded Live Series |
|
Wed, 03/06/2019 - 19:46 |
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity |
|
Tue, 03/05/2019 - 21:50 |
Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD) |
|
Mon, 03/04/2019 - 00:13 |
Allergan to Present at The Cowen and Company 39th Annual Health Care Conference |
|
Thu, 02/28/2019 - 23:50 |
Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C. |
|
Thu, 02/14/2019 - 23:14 |
Allergan to Present at The 8th Annual SVB Leerink Global Healthcare Conference |
|
Fri, 01/25/2019 - 10:55 |
Allergan Announces Increased Quarterly Dividend and Annual General Meeting of Shareholders Date |
|
Tue, 01/15/2019 - 12:10 |
CoolSculpting and Sonja Morgan Partner To Get Real About Self-Care |
|
Thu, 06/14/2018 - 06:22 |
Alliance Support and IME Grants |
|
Sun, 06/10/2018 - 23:01 |
< Responsibility Social Contract < Social Contract Social Responsibility < Social Responsibility Allergan Foundation < Allergan Foundation California Supply Chain Disclosure < California Supply Chain Disclosure Alliance Support and IME Grants < Alliance S |
|
Mon, 06/04/2018 - 23:24 |
California Supply Chain Disclosure |
|
Wed, 05/30/2018 - 08:36 |
Responsibility Social Contract < Social Contract Social Responsibility < Social Responsibility Allergan Foundation < Allergan Foundation California Supply Chain Disclosure < California Supply Chain Disclosure Alliance Support and IME Grants < Alliance Sup |
|
Tue, 07/01/2014 - 09:03 |
Forest partners with biotech and pharmaceutical companies around the world to develop and bring promising new medicines to market |
|
Tue, 07/01/2014 - 09:03 |
Forest identifies, develops, and delivers treatments that make a meaningful difference in people's lives |
|
Mon, 06/23/2014 - 09:38 |
Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development |
|
Tue, 06/17/2014 - 18:21 |
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4 |
|
Tue, 06/10/2014 - 18:21 |
Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA® TABLETS and Once-Daily NAMENDA XR® Into the Fall of 2014 |
|
Fri, 02/14/2014 - 17:36 |
Forest Laboratories to Discontinue NAMENDA® Tablets, Focus on Once-Daily NAMENDA XR® |
|
Mon, 02/03/2014 - 06:07 |
Forest Laboratories, Inc. Completes $2.9B Acquisition of Aptalis |
|
Wed, 01/08/2014 - 04:37 |
Forest Laboratories to Acquire Aptalis for $2.9 Billion in Cash |
|
Mon, 12/02/2013 - 07:52 |
Forest to Acquire U.S. Marketing Rights to Saphris® (asenapine) from Merck |
|
Mon, 12/02/2013 - 07:52 |
Forest Announces Major New Plans to Streamline Operations, Leverage Balance Sheet and Repurchase Common Stock |
|
Tue, 09/10/2013 - 08:54 |
Forest Laboratories Names Brent Saunders CEO and President |
|
Thu, 06/13/2013 - 06:24 |
Forest Announces U.S. Availability of New Once-Daily NAMENDA XR |
|
Thu, 05/09/2013 - 06:23 |
Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Hea |
|
Wed, 05/01/2013 - 06:24 |
Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combinat |
